Look back at pharma news in the week to May 1, 2020
By Barbara Obstoj-Cardwell. Editor
Deal-making news last week included Japan’s Takeda Pharmaceutical’s collaboration with ProThera Biologics to develop a novel plasma-based IAIP therapy for acute inflammatory conditions. Research news featured a disappointment for Blueprint Medicines with the release of top-line Phase III results for its gastrointestinal stroma tumor (GIST) drug Ayvakit (avapritinib) that failed. Meantime, Sanofi and partner Regeneron Pharmaceuticals presented data on their trial of the repurposed drug Kevzara as a potential therapy for COVID-19, as well as long-awaited positive data for Gilead Sciences’ anti-viral drug remdesivir in the COVID-19 setting and also from the NIAID study of the drug. Elsewhere, news of the US Food and Drug Administration approval for Neurocrine’s Parkinson’s disease drug Ongentys was welcome, but the decision to not launch the drug immediately due to the COVID-19 pandemic, while partly expected, was not.
Takeda collaborates with ProThera
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze